AKR1C1‑3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies

Zhao,Shou‑Feng; Wang,Shu‑Guo; Zhao,Zi‑Yun; Li,Wen‑Li

doi:10.3892/ol.2019.10802

AKR1C1‑3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies

Authors:
- Shou‑Feng Zhao
- Shu‑Guo Wang
- Zi‑Yun Zhao
- Wen‑Li Li
View Affiliations

Affiliations: Central Laboratories, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China, Department of Clinical Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China, Department of Laboratory Medicine, Qingdao Central Hospital, Qingdao, Shandong 266044, P.R. China, Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China
Published online on: September 4, 2019 https://doi.org/10.3892/ol.2019.10802
Pages: 4515-4522
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aldo‑keto reductases, known as AKR1C1‑AKR1C4 enzymes, are pivotal to NADPH‑dependent reduction, and their expression is highly associated with the progression of malignant cancers. However, the expression and distinct prognostic value of the AKR1C family members in liver cancer are not well established. In the current study, the expression of AKR1C isoforms was studied using the Oncomine online databases. In addition, their expression profiles were analyzed in cancer cell lines using data from the Cancer Cell lines Encyclopedia (CCLE) database. Furthermore, the mRNA expression levels of AKR1C family members between liver cancer and normal liver samples were assessed by the Gene Expression Profiling Interactive Analysis (GEPIA) database. The AKR1C1‑3 prognostic value was further investigated by the Kaplan‑Meier plotter database in liver cancer patients. It was found that the expression levels of AKR1C3 were elevated significantly in liver cancer tissues and cells as demonstrated by the Oncomine, CCLE and GEPIA databases. The expression levels of AKR1C1 and AKR1C2 in liver cancer tissues did not increase significantly in the Oncomine database while expression was significantly high in CCLE and GEPIA databases. However, the expression levels of the AKR1C4 gene as determined by the CCLE, GEPIA and Oncomine databases were not consistent. Therefore, the Kaplan‑Meier survival curves of liver cancer patients with the expression of AKR1C1‑3 genes were next analyzed. The data indicated that high expression levels of AKR1C1‑3 were correlated with lower overall survival in liver cancer patients. Using the co‑expression and PPI network, AKR1C1‑3 genes were identified that were involved in the same pathway displaying 44 total unique interactors. These results suggested that the increased AKR1C1‑3, notably AKR1C3 expression levels served as possible diagnostic biomarkers and essential prognostic factors for liver cancer patients. The roles of AKR1C4 in liver cancer require further examination.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH and Marrero JA: Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 67:358–380. 2018. View Article : Google Scholar : PubMed/NCBI
3	Liu S, Miao R, Zhai M, Pang Q, Deng Y, Liu S, Qu K, Liu C and Zhang J: Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap. Oncotarget. 8:47412–47424. 2017.PubMed/NCBI
4	Black AP and Mehta AS: The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome. Curr Opin Pharmacol. 41:74–78. 2018. View Article : Google Scholar : PubMed/NCBI
5	Behne T and Copur MS: Biomarkers for hepatocellular carcinoma. Int J Hepatol. 2012:8590762012. View Article : Google Scholar : PubMed/NCBI
6	Zhao YJ, Ju Q and Li GC: Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 1:593–598. 2013. View Article : Google Scholar : PubMed/NCBI
7	Barski OA, Mindnich R and Penning TM: Alternative splicing in the Aldo-Keto reductase superfamily: Implications for protein nomenclature. Chem Biol Interact. 202:153–158. 2013. View Article : Google Scholar : PubMed/NCBI
8	Rizner TL and Penning TM: Role of Aldo-Keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids. 79:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
9	Frycz BA, Murawa D, Borejsza-Wysocki M, Wichtowski M, Spychała A, Marciniak R, Murawa P, Drews M and Jagodziński PP: Transcript level of AKR1C3 is down-regulated in gastric cancer. Biochem Cell Biol. 94:138–146. 2016. View Article : Google Scholar : PubMed/NCBI
10	Sun SQ, Gu X, Gao XS, Li Y, Yu H, Xiong W, Yu H, Wang W, Li Y, Teng Y and Zhou D: Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation. Oncotarget. 7:48050–48058. 2016.PubMed/NCBI
11	Lewis MJ, Wiebe JP and Heathcote JG: Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer. 4:272004. View Article : Google Scholar : PubMed/NCBI
12	Wenners A, Hartmann F, Jochens A, Roemer AM, Alkatout I, Klapper W, van Mackelenbergh M, Mundhenke C, Jonat W and Bauer M: Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. Int J Clin Oncol. 21:548–556. 2016. View Article : Google Scholar : PubMed/NCBI
13	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated Data-Mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
14	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
15	Győrffy B, Surowiak P, Budczies J and Lánczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in Non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
16	Győrffy B, Lánczky A and Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
17	Menyhart O, Nagy A and Gyorffy B: Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 5:1810062018. View Article : Google Scholar : PubMed/NCBI
18	Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
19	Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
20	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43((Database Issue)): D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
21	Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al: Gene expression patterns in human liver cancers. Mol Biol Cell. 13:1929–1939. 2002. View Article : Google Scholar : PubMed/NCBI
22	Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, et al: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 45:938–947. 2007. View Article : Google Scholar : PubMed/NCBI
23	Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
24	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
25	Hevir N, Vouk K, Sinkovec J, Ribic-Pucelj M and Rizner TL: Aldo-Keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chem Biol Interact. 191:217–226. 2011. View Article : Google Scholar : PubMed/NCBI
26	Tian H, Li X, Jiang W, Lv C, Sun W, Huang C and Chen R: High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells. Lung Cancer (Auckl). 7:53–61. 2016.PubMed/NCBI
27	Tiryakioglu NO and Tunali NE: Association of AKR1C3 Polymorphisms with bladder cancer. Urol J. 13:2615–2621. 2016.PubMed/NCBI
28	Lu D, Zhang X and Cao X: The effect of AKR1C2 gene on hepatocarcinogenesis and its abnormal expression in hepatocellular carcinoma from Qidong, China, a liver cancer high risk area. Progress Biochemistry Biophysics. 30:906–918. 2003.
29	Zhong T, Xu F, Xu J, Liu L and Chen Y: Aldo-Keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss. Biomed Pharmacother. 69:317–325. 2015. View Article : Google Scholar : PubMed/NCBI
30	Xiong W, Zhao J, Yu H, Li X, Sun S, Li Y, Xia Q, Zhang C, He Q, Gao X, et al: Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress. PLoS One. 9:e1119112014. View Article : Google Scholar : PubMed/NCBI
31	Zeng CM, Chang LL, Ying MD, Cao J, He QJ, Zhu H and Yang B: Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, regulation, and intervention for Anti-cancer therapy. Front Pharmacol. 8:1192017. View Article : Google Scholar : PubMed/NCBI
32	Dhanasekaran R, Limaye A and Cabrera R: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37. 2012.PubMed/NCBI
33	Abbattista MR, Jamieson SM, Gu Y, Nickel JE, Pullen SM, Patterson AV, Wilson WR and Guise CP: Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biol Ther. 16:610–622. 2015. View Article : Google Scholar : PubMed/NCBI